Treatment of hepatitis C: the use of the new pangenotypic direct‐acting antivirals in “special populations”

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|38|S1|28-33

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.38, Iss.S1, 2018-02, pp. : 28-33

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hepatitis C virus‐related symptoms, but not quality of life, were improved by treatment with direct‐acting antivirals

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E232-E239

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct‐acting anti‐virals

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 866-876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: direct‐acting antivirals significantly improve quality of life in patients with hepatitis C virus infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 536-537

John Wiley & Sons Inc

Access to resources Recommend Favorite

Minimum target prices for production of direct‐acting antivirals and associated diagnostics to combat hepatitis C virus

By  

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1174-1182

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prednisolone does not affect direct‐acting antivirals against hepatitis C, but inhibits interferon‐alpha production by plasmacytoid dendritic cells

By  

TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol. 17, Iss. 5, 2015-10 ,pp. : 707-715

John Wiley & Sons Inc

Access to resources Recommend Favorite